| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.57 | 12.18 | 54.41 | 5.97 |
Op profit growth | 19.2 | 3.1 | 93.35 | -15.35 |
EBIT growth | 14.8 | -1.65 | 80.53 | -21.86 |
Net profit growth | -12.43 | -1.02 | 100.91 | -39.16 |
Profitability ratios (%) | ||||
OPM | 24.07 | 23.13 | 25.17 | 20.1 |
EBIT margin | 16.72 | 16.69 | 19.03 | 16.28 |
Net profit margin | 7.92 | 10.36 | 11.75 | 9.03 |
RoCE | 9.58 | 10.3 | 13.36 | 8.59 |
RoNW | 2.01 | 2.58 | 3.14 | 1.85 |
RoA | 1.13 | 1.59 | 2.06 | 1.19 |
Per share ratios (₹) | ||||
EPS | 6.43 | 7.05 | 7.26 | 7.55 |
Dividend per share | 0.5 | 0 | 0 | 1 |
Cash EPS | -1.38 | 0.21 | 1.63 | -0.21 |
Book value per share | 70.23 | 63.55 | 55.88 | 86.34 |
Valuation ratios | ||||
P/E | 52.02 | 57.98 | 37.27 | 39.35 |
P/CEPS | -242.25 | 1,931.33 | 165.67 | -1,403.62 |
P/B | 4.76 | 6.43 | 4.84 | 3.44 |
EV/EBIDTA | 19.95 | 27.01 | 19.37 | 34.63 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 16.11 |
Tax payout | -16.25 | -19.52 | -27.46 | -25.72 |
Liquidity ratios | ||||
Debtor days | 79.42 | 69.67 | 65.56 | 86.17 |
Inventory days | 92.87 | 84.37 | 61.86 | 60.09 |
Creditor days | -112.21 | -121.03 | -113.98 | -119.99 |
Leverage ratios | ||||
Interest coverage | -20.24 | -20.66 | -18.67 | -10.91 |
Net debt / equity | 0.4 | 0.32 | 0.25 | 0.18 |
Net debt / op. profit | 1.72 | 1.49 | 1.07 | 1.13 |
Cost breakup (₹) | ||||
Material costs | -33.21 | -31.41 | -32.23 | -39.67 |
Employee costs | -22.97 | -24.37 | -22.91 | -22.58 |
Other costs | -19.73 | -21.07 | -19.68 | -17.63 |
The drug shall be used to treat diet and exercise for improvement of glycemic control in adults with type 2 diabetes.
Here are some of the stocks that may see significant price movement today: Interglobe Aviation, Tata Consultancy, Oil India, etc.
Biosimilars revenue grew 18% YoY to ₹2,458 crore in the quarter. This growth was driven by sustained global demand
As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.
Here are some of the stocks that may see significant price movement today: United Spirits, Biocon, NATCO Pharma, etc.
Here are some of the stocks that may see significant price movement today: Hyundai Motor, Biocon, Zee Entertainment, etc.
Biocon has appointed Kotak Mahindra Capital, Goldman Sachs (India), and BofA Securities India as lead advisors for the transaction
In its filing with the bourses, the company reported that the current contract period of 36 months has been extended for an additional six months.
As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.
The operating performance was also good as EBITDA increased 17.7% to ₹1,078.2 crore in March quarter compared with ₹915.9 crore in Q4 FY24.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
